Silence Therapeutics plc
SLN
$7.35
$0.456.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 43.84% | 23.38% | 4.12% | -331.91% | 134.61% |
| Total Depreciation and Amortization | -27.56% | 5.41% | 7.25% | -1.43% | -7.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -186.79% | -91.46% | 77.50% | 160.82% | -172.45% |
| Change in Net Operating Assets | -154.00% | 301.31% | -142.91% | 134.14% | -958.56% |
| Cash from Operations | -58.73% | 50.00% | -76.98% | 55.21% | -7.32% |
| Capital Expenditure | 100.00% | 93.75% | -1,100.00% | 93.55% | 3.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -203.99% | 3,487.85% | 96.59% | -167.05% | 273.83% |
| Cash from Investing | -204.00% | 3,383.55% | 96.48% | -167.12% | 273.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -92.86% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -92.86% | 114.29% | -101.23% |
| Foreign Exchange rate Adjustments | -21.70% | -153.54% | -14.66% | 245.91% | -159.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -275.60% | 274.07% | 58.99% | -247.04% | 169.16% |